NCT03493945
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Symptomatic brain or CNS metastases
https://ClinicalTrials.gov/show/NCT03493945